148 related articles for article (PubMed ID: 34589958)
1. Novel
Jiao Y; Liu M; Luo N; Guo H; Li J
JTO Clin Res Rep; 2020 Nov; 1(4):100079. PubMed ID: 34589958
[No Abstract] [Full Text] [Related]
2. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
Wang LS; Chen SQ; Zhong X; Jiao XD; Liu K; Qin BD; Wu Y; Ling Y; Duan XP; Zang YS
Anticancer Drugs; 2023 Nov; 34(10):1146-1150. PubMed ID: 36728908
[TBL] [Abstract][Full Text] [Related]
3. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
[TBL] [Abstract][Full Text] [Related]
4. ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer.
Hou H; Sun D; Zhang C; Liu D; Zhang X
Thorac Cancer; 2021 Mar; 12(6):962-969. PubMed ID: 33506568
[TBL] [Abstract][Full Text] [Related]
5.
von Buttlar X; Reuss JE; Liu SV; Kim C
JTO Clin Res Rep; 2021 Jun; 2(6):100179. PubMed ID: 34590027
[TBL] [Abstract][Full Text] [Related]
6. Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
Rotow J; Patel JD; Hanley MP; Yu H; Awad M; Goldman JW; Nechushtan H; Scheffler M; Kuo CS; Rajappa S; Harada G; Clifford S; Santucci A; Silva L; Tupper R; Oxnard GR; Kherani J; Drilon A
Clin Cancer Res; 2023 Aug; 29(16):2979-2987. PubMed ID: 36996322
[TBL] [Abstract][Full Text] [Related]
7. Genomic characterization of a PPP1CB-ALK fusion with fusion gene amplification in a congenital glioblastoma.
Zhong Y; Lin F; Xu F; Schubert J; Wu J; Wainwright L; Zhao X; Cao K; Fan Z; Chen J; Lang SS; Kennedy BC; Viaene AN; Santi M; Resnick AC; Storm PB; Li MM
Cancer Genet; 2021 Apr; 252-253():37-42. PubMed ID: 33341678
[TBL] [Abstract][Full Text] [Related]
8. Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
Zeng Q; Gao H; Zhang L; Qin S; Gu Y; Chen Q
Anticancer Drugs; 2021 Sep; 32(8):890-893. PubMed ID: 34232939
[TBL] [Abstract][Full Text] [Related]
9. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib.
Castellano GM; Aisner J; Burley SK; Vallat B; Yu HA; Pine SR; Ganesan S
J Thorac Oncol; 2019 Nov; 14(11):1982-1988. PubMed ID: 31254668
[TBL] [Abstract][Full Text] [Related]
10. Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.
Zeng Y; Feng Y; Fu G; Jiang J; Liu X; Pan Y; Hu C; Liu X; Wu F
Front Pharmacol; 2022; 13():838247. PubMed ID: 35462930
[TBL] [Abstract][Full Text] [Related]
11. Targeting
Aboubakar Nana F; Ocak S
Pharmaceutics; 2021 Sep; 13(9):. PubMed ID: 34575554
[TBL] [Abstract][Full Text] [Related]
12. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.
Arai S; Takeuchi S; Fukuda K; Taniguchi H; Nishiyama A; Tanimoto A; Satouchi M; Yamashita K; Ohtsubo K; Nanjo S; Kumagai T; Katayama R; Nishio M; Zheng MM; Wu YL; Nishihara H; Yamamoto T; Nakada M; Yano S
J Thorac Oncol; 2020 May; 15(5):752-765. PubMed ID: 31972351
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
[TBL] [Abstract][Full Text] [Related]
14. APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas.
Selenica P; Marra A; Choudhury NJ; Gazzo A; Falcon CJ; Patel J; Pei X; Zhu Y; Ng CKY; Curry M; Heller G; Zhang YK; Berger MF; Ladanyi M; Rudin CM; Chandarlapaty S; Lovly CM; Reis-Filho JS; Yu HA
Ann Oncol; 2022 Dec; 33(12):1284-1295. PubMed ID: 36089134
[TBL] [Abstract][Full Text] [Related]
15. A Novel
Sun Y; Pei L; Luo N; Chen D; Meng L
Onco Targets Ther; 2020; 13():11177-11181. PubMed ID: 33173309
[TBL] [Abstract][Full Text] [Related]
16. Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.
Wang JL; Wang LS; Zhu JQ; Ren J; Wang D; Luo M
Respirol Case Rep; 2022 Nov; 10(11):e01054. PubMed ID: 36258694
[TBL] [Abstract][Full Text] [Related]
17. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
18. Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in
Schoenfeld AJ; Chan JM; Kubota D; Sato H; Rizvi H; Daneshbod Y; Chang JC; Paik PK; Offin M; Arcila ME; Davare MA; Shinde U; Pe'er D; Rekhtman N; Kris MG; Somwar R; Riely GJ; Ladanyi M; Yu HA
Clin Cancer Res; 2020 Jun; 26(11):2654-2663. PubMed ID: 31911548
[TBL] [Abstract][Full Text] [Related]
19. Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in
Namba K; Shien K; Takahashi Y; Torigoe H; Sato H; Yoshioka T; Takeda T; Kurihara E; Ogoshi Y; Yamamoto H; Soh J; Tomida S; Toyooka S
Mol Cancer Res; 2019 Feb; 17(2):499-507. PubMed ID: 30463991
[TBL] [Abstract][Full Text] [Related]
20. Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models.
Lim SM; Yang SD; Lim S; Heo SG; Daniel S; Markovets A; Minoo R; Pyo KH; Yun MR; Hong MH; Kim HR; Cho BC
Ther Adv Med Oncol; 2022; 14():17588359221079125. PubMed ID: 35251316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
